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Introduction: In refractory status epilepticus (SE), because of subcellular maladaptive changes, GABAergic drugs
are no longer effective, and the excitatory neurotransmitter glutamate (Glu) plays a major role in seizure
perpetuation. Perampanel (PER, licensed since 09/2012) is the ﬁrst orally active noncompetitive AMPA receptor
antagonist for adjunctive treatment of refractory focal epilepsy.
Methods: We analyzed treatment response, seizure outcome, and adverse effects of add-on treatment with
perampanel in patients with refractory status epilepticus in the Neurological Intensive Care Unit (NICU),
Salzburg, Austria between 09/2012 and 11/2014 by retrospective chart review.
Results: Twelve patients (75%women)with refractory status epilepticus were treatedwith PER administered per
nasogastric tube between 09/2012 and 11/2014. Median age was 75 years [range: 60–91]. The most frequent SE
type was nonconvulsive SE (NCSE) with (5/12, 42%) and without coma (6/12, 50%). In seven patients (58%), SE
arose de novo, with an acute symptomatic cause in ﬁve patients (42%). Cerebrovascular diseases (4/12, 33%) and
cerebral tumors (4/12, 33%)were themost common etiologies. Perampanel was given after a median number of
four antiepileptic drugs [range: 2–7] and amedian time of 1.5 days [range: 0.8–18.3]. In one patient (8%), clinical
improvement was observed within 24 h and EEG improvement within 60 h after administration of PER, while in
another patient (8%), clinical and EEG improvement was observed more than 48 h after administration. Median
initial dose was 4 mg [range: 2–12; SD: 4.11], titrated up to a median of 12 mg [range: 4–12] in steps of 2 to
4 mg per day. No adverse effects were reported regarding cardiorespiratory changes or laboratory parameters.
Outcomes after SE were moderate disability in ﬁve patients (42%), death in three patients (25%), and persistent
vegetative state in two patients (17%).
Conclusion: Though glutamate plays a major role in seizure perpetuation, the noncompetitive AMPA receptor
antagonist PER could only ameliorate seizure activity in a few patients with refractory SE. The long duration
of SE before the administration of PER via nasogastric tube, as well as relatively low doses of PER, might be
responsible for the modest result. Perampanel was well tolerated, and no adverse events were reported.This article is part of a Special Issue entitled Status Epilepticus.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Status epilepticus (SE) is a prolonged, self-sustaining seizure
associated with high morbidity [1] and mortality rates up to 20% [2,3].gy, CDK, Paracelsus Medical
tria. Tel.: +43 662 4483 3001;
j.hoeﬂer@salk.at (J. Höﬂer),
er), g.kuchukhidze@salk.at
salk.at (J. Dobesberger),
.zerbs@salk.at (A. Zerbs),
. This is an open access article underAccording to a new deﬁnition, status epilepticus is the failure of the
mechanisms responsible for seizure termination or the initiation of
mechanisms, which leads to abnormally prolonged seizures (t1) that
might have long-term consequences (t2), including neuronal death,
neuronal injury, and alteration of neuronal networks, depending on
the type and duration of seizures [4]. An imbalance of the inhibitory
activity of the neurotransmitter γ-amino butyric acid (GABA) and the
excitatory neurotransmitter glutamate is suspected as the underlying
pathophysiology of seizure perpetuation in status epilepticus [5,6].
Fast and aggressive treatment of SE is important as survival rates
decreasewith seizure duration [7]. Treatment follows a staged approach
with intravenous benzodiazepines, followed by intravenous AEDs. Ifthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Demographic and clinical data of patients with refractory SE who received perampanel.
Total
N= 12 (%)
Survivors
N = 9 (%)
Nonsurvivors
N = 3 (%)
Gender (female) 9 (75) 7 (78) 2 (66)
Preexisting epilepsy 5 (42) 4 (44) 1 (33)
Insufﬁcient AED levels 1 (25) 1 (11) 0 (0)
Type of SE Acute symptomatic 5 (42) 5 (56) 0 (0)
Remote symptomatic 5 (42) 2 (22) 3 (100)
Progressive symptomatic 2 (16) 2 (22) 0 (0)
Etiology Cerebrovascular 4 (33) 3 (33) 1 (33)
Posttraumatic 2 (17) 0 (0) 2 (66)
Metabolic 1 (8.5) 1 (11) 0 (0)
CNS infection 1 (8.5) 1 (11) 0 (0)
CNS tumor 4 (33) 4 (44) 0 (0)
SE type Tonic–clonic 0 (0) 0 (0) 0 (0)
Focal motoric 1 (8) 1 (11) 0 (0)
NCSE without coma 5 (42) 4 (44) 1 (33)
NCSE with coma 6 (50) 4 (44) 2 (66)
EEG patterns LPD 6 (50) 5 (55) 1 (33)
GPD 1 (8.5) 0 (0) 1 (33)
Spontaneous burst
suppression
1 (8.5) 0 (0) 1 (33)
Rhythmic delta activity 4 (33) 4 (44) 0 (0)
GlasgowOutcome
Scale (GOS)
Good recovery 0 (0) 0 (0) 0 (0)
Moderate disability 5 (42) 5 (56) 0 (0)
Severe disability 2 (17) 2 (22) 0 (0)
Persistent vegetative state 2 (17) 2 (22) 0 (0)
Dead 3 (25) 0 (0) 3 (100)
Abbreviations: GPDs — generalized periodic discharges, LPDs — lateralized periodic
discharges.
355A. Rohracher et al. / Epilepsy & Behavior 49 (2015) 354–358seizure activity is ongoing, despite these interventions, SE is considered
refractory, with urgent need of intensive care treatment and intrave-
nous anesthetics [8,9]. At this stage, subcellular maladaptive changes
with internalization of postsynaptic GABAA receptors to the cytoplasm
and changes in chloride homeostasis [5,6,10] make GABAergic drugs
less efﬁcacious or eventually ineffective. The excitatory neurotransmit-
ter glutamate plays a major role in seizure perpetuation via alpha-
amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) recep-
tors at this stage.
Perampanel (PER) is the ﬁrst orally active, noncompetitive AMPA re-
ceptor antagonist and was licensed by the EMA in 09/2012 for the ad-
junctive treatment of focal onset epilepsy in patients ≥12 years old. In
a lithium–pilocarpine rat model of SE, the efﬁcacy of diazepam and
PER in refractory SEwas assessed [11]. In this study, PER terminated sei-
zure activity when administered 10 min (ED50: 1.7 mg/kg) and 30 min
(ED50: 5.1 mg/kg) after SE onset, whereas diazepam 30 mg/kg did not
terminate seizure activity at 30 min. Perampanel 8 mg/kg terminated
seizure activity in all rats whether administered at 10 or 30min, thoughRhythmic Sharp Wave activity < 2.5 Hz right temporal I
Fig. 1. Responder 1: Initial EEG and Estrong CNS depressant effects (immobility, loss of righting reﬂex) were
observed. Hence, efﬁcacy of PER in the termination of benzodiazepine-
resistant SE was suggested, consistent with previous studies with
other antiglutamatergic drugs in animal models [12–14]. Furthermore,
a synergistic effect of coadministered low-dose diazepam (5 mg/kg)
and PER (1mg/kg) 30min after SE onset resulted in seizure termination
in all rats with only slight CNS depressant effects [15].
Data on the efﬁcacy of perampanel in the treatment of refractory SE
in humans are missing. So far, there is only one case report on possible
termination of focal SE (PER added as the last AED within 24 h of SE
termination) in an 81-year-old patient [15].
The aim of our studywas to evaluate efﬁcacy and safety of treatment
with PER in patients with refractory and super-refractory SE in a
neurological intensive care unit (NICU).
2. Material and methods
All patients who received perampanel (PER) as an add-on treatment
in refractory and super-refractory SE at the Neurological Intensive Care
Unit (NICU), Salzburg, Austria between 09/2012 and 11/2014 were
analyzed. By retrospective chart review, we collected data on underlying
SE etiology, SE type, SE duration, duration of stay in the NICU and in the
hospital, number and sequence of administered AEDs before PER, re-
sponse to PER treatment within 24, 48, and 72 h, outcome after SE, and
adverse effects of the add-on treatment with perampanel.
The diagnosis of SE was made either clinically, in the case of SE with
prominent motor symptoms, or using electroclinical criteria for NCSE
proposed by Kaplan and Sutter [16] and Beniczky et al. [17].
We used a clinical classiﬁcation of SE types according to seizure
semiology based on the proposal of the ILAE Task Force along with
two taxonomic criteria: presence of motor symptoms and impairment
of consciousness [4]. Hence, we distinguished between the following:
(a) SE with prominent motor symptoms (including tonic–clonic SE,
myoclonic SE, focal motoric SE, tonic SE and hyperkinetic SE) and (b) SE
without prominent motor symptoms (NCSE) with or without coma.
With regard to etiology, we distinguished between symptomatic (or
known cause) — which was further classiﬁed as acute symptomatic,
remote symptomatic, and progressive symptomatic — and cryptogenic
(or unknown cause) [18].
Status epilepticus severity score (STESS, cutoff level for bad
outcome: 3 points) [19] and Epidemiology-based mortality score in SE
(EMSE, cutoff level for bad outcome: 64 points) [20] were used to
estimate mortality risk.
Treatment followed a staged approach with stage one (intravenous
benzodiazepines) and stage two (intravenous AEDs such as levetirace-
tam (LEV), phenytoin (PHT), valproic acid (VPA), or lacosamiderregular Theta/Delta activity right temoral with intermittent SW
EG improvement 60 h after PER.
Periodic Sharp Wave activity left temporal with fluctuation Irregular Theta/Delta activity left temporal with intermittent SW 
Fig. 2. Responder 2: Initial EEG and EEG improvement 48 h after PER.
356 A. Rohracher et al. / Epilepsy & Behavior 49 (2015) 354–358(LCM)) treatments. In case of ongoing seizure activity (clinically or
ascertained by persistent EEG pattern) despite stage one and two treat-
ments, SE was deﬁned as refractory, and stage 3 treatment with
propofol (PRO), midazolam (MDZ), or thiopental (THIO) was
administered. Super-refractory SE was deﬁned as persistent seizure
activity for more than 24 h despite intravenous anesthetics. At this
stage, other treatment options like intravenous ketamine (KET),
magnesium (Mg), intravenous immunoglobulin (IVIG), and other new
AEDs were given, according to the judgment of the ammending
physician.
Treatment response after the administration of PER was assessed
based on clinical and EEG changes within 24 h and, because of the
long half-life of perampanel (105 h), between 24 and 72 h, if no further
therapywas added throughout that period of time. If another treatment
was given within that time period, only those clinical and EEG changes
prior to the succeeding drug were considered a response to PER.
Outcome after cessation of SE (deﬁned as termination of clinical
symptoms or cessation of seizure activity in the EEG) was assessed
according to the Glasgow Outcome Scale (GOS) as follows: good
recovery, moderate disability, severe disability, persistent vegetative
state, and death. Death was rated if it occurred within 8 weeks of status
epilepticus.
Blood samples including hemogram, C-reactive protein, basic
metabolic panel including electrolytes, blood urea nitrogen, creatinine,
glucose, liver enzymes, and levels of concomitant AEDswere taken reg-
ularly. All patientswere under continuous cardiorespiratorymonitoring
at our NICU.2.1. Statistics
Descriptive statistical analysis including calculation of frequencies as
well as calculation ofmedian [range], mean, and standard deviationwas
performed using Microsoft Excel. Because of the small sample size, noTable 2
Clinical data of patients with refractory SE who received perampanel.
Total N = 12
Median [range]
Age, years; median (range) 75 [60–91]
Stay in the NICU (days) 9 [4–21]
Stay in the hospital (days) 18 [6–70]
Number of AEDs prior to PER 4 [2–7]
Dose of PER 12 [4–12]
Abbreviations: AED — antiepileptic drug, NICU — neurological intensive care unit, PER — peramstatistical comparison between responders and nonresponders as well
as between survivors and nonsurvivors was performed.
2.2. Standard protocol approvals, registrations, and patient consents
This is a retrospective noninvasive study, which does not require
ethics committee approval according to the Austrian Law on Research.
3. Results
Twelve patients (75% women) with refractory status epilepticus
were treated with PER administered per nasogastric tube in the NICU
between 09/2012 and 11/2014. Median age was 75 years [range:
60–91; SD: 10.8]. The most frequent SE type was nonconvulsive SE
(NCSE) with (5/12, 42%) and without coma (6/12, 50%). In seven
patients (58%), SE arose de novo, with an acute symptomatic cause in
ﬁve patients (42%). Cerebrovascular diseases (4/12, 33%) and cerebral
tumors (4/12, 33%) were the most common etiologies. In one patient
with preexisting epilepsy, subtherapeutic plasma levels of the
prescribed AEDs were assigned as cause of SE. For further details on pa-
tients' demographics, see Table 1. Status epilepticus lasted less than 24 h
in 7 patients (58%), which is deﬁned as refractory SE, while that of the
other 5 patients were classiﬁed as super-refractory SE with SE duration
of one to seven days in three patients (25%) andmore than 7 days in two
patients (17%). Perampanel was given after a median number of four
AEDs [range: 2–7] (for detailed therapeutic approach, see Fig. 1) and a
median time of 1.5 days [range: 0.8–18.3]. Median initial dose was
4 mg [range: 2–12; SD: 4.11], titrated up to a median of 12 mg [range
4–12] in increments of 2 to 4 mg per day. Nine patients (75%) received
phenytoin (PHT) as a concomitant AED treatment.
In two patients (17%), clinical improvement (improvement of
vigilance, adequate responses, absence of subtle clinical ictal signs)
was observed within 24 h after the administration of PER, whereinSurvivors N = 9
Median [range]
Nonsurvivors N = 3
Median [range]
72 [60–91] 88 [64–88]
8 [4–21] 16 [8–22]
18 [6–60] 18 [16–40]
4 [2–7] 6 [4–6]
12 [4–12] 12 [8–12]
panel.
Table 3
Clinical data of responders to perampanel.
Responder 1 Responder 2
Age, years 60 77
Preexisting epilepsy Yes No
Etiology Tumor Meningioma
SE type NCSE without coma NCSE with coma
EEG pattern LPD, rh SW b 2.5 Hz LPD
Number of AEDs 7 4
STESS score 0 5
EMSE score 82 65
Initial dose PER 6 mg 6 mg
Titration interval 6 mg/d 2 mg/d
Maximum dose 12 mg 12 mg
Stay in the NICU (days) 21 8
Stay in the hospital (days) 60 25
GOS Moderate disability Severe disability
AEDs LZP, LEV, LCM, PHT, MDZ, TPM, CBZ LZP, LEV, PHT, VPA
Abbreviations: CBZ— carbamazepine, GOS— GlasgowOutcome Scale, LCM— lacosamide,
LEV — levetiracetam, LPDs — lateralized periodic discharges, LZP — lorazepam, MDZ —
midazolam, PHT — phenytoin, rh SW — rhythmic sharp wave, TPM — topiramate, VPA —
valproic acid.
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considered a nonresponder. Clinical response in the other patient was
observed more than 6 h after the administration of PER at a maximum
dose of 12 mg, given 26 h after SE onset. Electroencephalographic
improvement in this patient followed clinical improvement and was
observed 60 h after the ﬁrst administration of PER. The initial EEG of
this patient showed right temporal rhythmic epileptiform discharges
b2.5 Hz (Fig. 1) and periodic lateralized epileptiform discharges
(PLEDs) with spatiotemporal evolution. Sixty hours after treatment ini-
tiation with PER, the EEG patterns changed and evolved into irregular
theta/delta activity with intermittent sharp waves and spikes in the
same location. In one further patient, clinical improvement was ob-
served 72 h after the administration of PER without other escalation of
therapy in between at a maximum dose of 12 mg of PER administered
28 h after SE onset. The initial EEG in this patient showed PLEDs (left
temporal maximum) with ﬂuctuation but no spatiotemporal evolution,
which stopped 48 h after PER administration before clinical improve-
ment (Fig. 2).
Outcomes after SE were moderate disability in ﬁve patients (42%),
persistent vegetative state in two patients (17%), and death in three
patients (25%). The patient with early treatment response had a com-
paratively good outcomewith moderate disability, and with severe dis-
ability to the one with late treatment response. In the group of
nonsurvivors, STESS score was true positive in two out of three patients
(66%), and EMSE in all three patients (100%). Altogether, STESS and
EMSE scores were positive in 8 out of 12 patients (75%) (STESS: PPV
25%, NPV 75%; EMSE: PPV 37.5%, NPV 100%) (see Tables 2–4).
Median stay in the NICU was 8.6 days [range: 4.1 to 21.3], while
median stay in the hospital was 18.3 days [range: 6.1 to 70.0].
No adverse effectswere reported regarding cardiorespiratory chang-
es or laboratory parameters related to the administration of PER in allTable 4
Antiepileptic drug treatment in refractory SE prior to PER treatment.
1st treatment 2nd treatment 3rd treatment
Lorazepam 11 (92%) 1 (8%)
Midazolam 1 (8%)
Levetirazetam 9 (75%) 1 (8%)
Phenytoin 2 (17%) 2 (17%)
Valproic acid 3 (25%)
Lacosamide 4 (33%)
Topiramate
Propofol
Ketamine
Carbamazepinepatients. Four patients (33%)were catecholamine-dependent on admis-
sion without documented increase of required doses after administra-
tion of PER. Plasma levels of concomitant AEDs were taken at a regular
basis, without changes in plasma concentration after starting therapy
with PER.
4. Discussion
Although glutamate plays a major role in seizure perpetuation in
refractory and super-refractory status epilepticus, and efﬁcacy of the
noncompetitive AMPA receptor antagonist PER was observed in lithi-
um–pilocarpine rat models with benzodiazepine-resistant SE [11], we
only observedmoderate response in our sample of patients with refrac-
tory and super-refractory SE in the NICU. The median initial dose in our
patientswas 4mg, titrated up to amaximumdose of 12mg given after a
median time of 1.5 days. The dose might be low compared to the pre-
clinical SEmodels. In rats, the effective dose atwhich SEwas terminated
in 50% of the rats (ED50) 30 min after SE onset was 5.1 mg/kg [11].
Furthermore, PER was administered intravenously in rats, whereas in
humans, there is only an oral formulation available, which we adminis-
tered via nasogastric tube. Perampanel administered orally is absorbed
in the upper gastrointestinal tract with a median time to reach maxi-
mum concentration concentration (Tmax) of 1 h (range: 0.5–10.0)
under fasting conditions in healthy subjects and a bioavailability of
100% when swallowed whole [21]. Bioavailability of perampanel ad-
ministered crushed via nasogastric tube has not been investigated, yet
solubility of PER is highest in acid conditions. Though not formally test-
ed, single case reports [22,23] suggest sufﬁcient bioavailability of PER
when administered via an enteral feeding tube. In critically ill patients,
gastrointestinal absorption is diminished because of slow gastric emp-
tying [24], reduced intestinal expression of glucose transporters [25],
as well as other suspected mechanisms like reduced intestinal blood
ﬂow and mucosal factors [24]. Hence, the oral administration of PER,
as well as its relatively low doses compared to the effective doses in
rats, might be one explanation for the comparatively poor treatment re-
sponse. Furthermore, PER has an apparent terminal half-life of ~105 h,
whereas the calculated effective half-life is 48 h, reaching a steady
state after 10 to 19 days [21]; therefore, assessment of treatment
response within 24 h might be too early. A comedication with
enzyme-inducing antiepileptic drugs, especially PHT in case of SE,
might inﬂuence PER plasma levels and, therefore, efﬁcacy of PER as
well. Plasma levels of PER could not be determined in our hospital;
therefore, we could not quantify this effect.
In addition, PER was given after a median time of 1.5 days, which
might have been too late in the course of SE. The subcellular changes
that lead to self-sustaining seizure activity are only partly discovered
[5,6]; they are not fully understood yet at such an advanced stage of
SE. An excessive seizure perpetuation, as seen in super-refractory SE,
might reﬂect the severe underlying dysfunction of the brain. These fac-
tors might contribute to the modest success of PER, when given at the
late stages of SE. In addition, our patient group was severely ill with
many factors contributing to a poor prognosis: (i) in 42% of our patients,4th treatment 5th treatment 6th treatment 7th treatment
1 (8%)
3 (25%) 1 (8%)
3 (25%)
1 (8%)
2 (17%) 2 (17%)
1 (8%) 1 (8%)
1 (8%) 1 (8%)
1 (8%)
358 A. Rohracher et al. / Epilepsy & Behavior 49 (2015) 354–358an acute symptomatic cause of SEwas identiﬁed, reﬂecting an acute and
severe brain damagewith a poorer prognosis; and (ii) themedian age of
our patients was 74.6 years, and STESS and EMSE scores were high,
suggesting a poor prognosis with a high negative predictive value of
the EMSE score of 100%.
5. Conclusions
Though glutamate plays a major role in seizure perpetuation of SE,
the noncompetitive AMPA receptor antagonist PER could only amelio-
rate seizure activity in a few patients with refractory and super-
refractory SE. The relatively low doses (compared to the effective
doses in animal models) of oral administration, the long duration of
SE before the administration of PER, and the severe underlying brain
dysfunction in patients with super-refractory SE might be responsible
for the modest results. Regarding safety issues, no adverse effects
could be observed both in cardiorespiratory and with respect to labora-
tory results including kidney function and liver enzymes. Hence, con-
trolled testing for tolerability and safety of higher doses of PER in the
treatment of SE as well as the earlier use of PER in refractory SE is war-
ranted and a parenteral formulamight increase treatment response and
improve outcome.
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